The company's Advanced Technologies Division has developed a pair of pre-prototype assays for HSV-1 and HSV-2 antibody detection.* The key achievements of this development are:
The company was also pleased that, at this early stage in the project, the results were obtained in less than 50% of the time taken on current ELISA technology.
The development of the assays has also enabled the project team to demonstrate that the design of the antigen used in the assay can have a positive impact on its performance despite the presence of potentially interfering substances in the sera used for testing.
Paul Nitz, Panbio Chief Executive Officer said, "We are pleased with the progress the project team has made. While a number of technical challenges remain, these results increase our confidence of reaching our next goal which is to produce a prototype assay for pre-clinical evaluation by the end of 2006."
Panbio will be presenting a poster at the American Association of Clinical Chemistry (AACC) meeting in Chicago on July 27 outlining the development of the Homogeneous Assay technology to date. The AACC meeting is one of the premier meetings in the world for the medical diagnostics industry. The company will be discussing the progress of the project with a number of potential licensees of the technology.
Published on PsychCentral.com. All rights reserved.